isocarboxazid has been researched along with Huntington Disease in 1 studies
Isocarboxazid: An MAO inhibitor that is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in the treatment of panic disorder and the phobic disorders. (From AMA, Drug Evaluations Annual, 1994, p311)
Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
Excerpt | Relevance | Reference |
---|---|---|
"Depression is common in Huntington's disease." | 1.27 | Treatment of depression in Huntington's disease with monoamine oxidase inhibitors. ( Ford, MF, 1986) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ford, MF | 1 |
1 other study available for isocarboxazid and Huntington Disease
Article | Year |
---|---|
Treatment of depression in Huntington's disease with monoamine oxidase inhibitors.
Topics: Adult; Aged; Depression; Female; Humans; Huntington Disease; Isocarboxazid; Middle Aged; Monoamine O | 1986 |